 to quantify regional myocardial perfusion with 82/RbCl and 62/Cu- pyruvaldehyde bis(N/4-methylthiosemicarbazone) (PTSM). We demonstrated however that 62/Cu-PTSM binds to human albumin limiting the ability to quantify flow after pharmacologically-induced hyperemia
to quantify regional myocardial perfusion with 82 / RbCl and 62 / Cu- pyruvaldehyde bis(N/4 - methylthiosemicarbazone) (PTSM). We demonstrated however that 62 / Cu - PTSM binds to human albumin limiting the ability to quantify flow after pharmacologically - induce hyperemia
 to quantify regional myocavdial perfusion cuth 82/RbRl and 62/Du- pyruvxldehyde bis(N/4-methylthiosemicerbazone) (KNSM). We demonstrated huwever thwt 62/Cu-PTSN biids to human albnjin limlcing fme abnlmty to quantify flow aftes pharmacologiwaulv-induced hyperemia
to quantify regional myocardial perfusion with 82/RbCl pyruvaldehyde (PTSM). We however that 62/Cu-PTSM the to quantify flow pharmacologically-induced hyperemia
 to quantify regional myocardIal perfusiOn witH 82/Rbcl aNd 62/cu- pyRuvaLdehyde bis(N/4-metHYlthIosemicarbazone) (PTSM). We dEmonsTrATed hOWeVer thAt 62/Cu-PTSm BiNDS to HuMaN alBuMIn LimitIng The abilIty to quantIfy FlOw after pharmACoLogically-iNduCed hyperemia
 to quantify regional myoc ardial per fusio n w ith  8 2/Rb Cl a nd 62/Cu- pyru v alde hyde bis(N/4-methylthi osemi ca r bazo n e)  (PTS M). Wed em o n str at ed  ho we v er  that  62 /Cu-PTS M binds to  hu ma n albumin li m it ing the ab ili ty to quanti fyflow a ft erp harma col ogica lly-in d uced h yperemia
 to_quantify regional_myocardial perfusion with 82/RbCl_and 62/Cu-_pyruvaldehyde_bis(N/4-methylthiosemicarbazone) (PTSM)._We_demonstrated however that_62/Cu-PTSM binds to_human albumin limiting the_ability to quantify_flow_after pharmacologically-induced hyperemia